- Home
- TNGX vs SRDX Comparison
TNGX vs SRDX Comparison
Compare TNGX & SRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- SRDX
- Stock Information
- Founded
- TNGX 2014
- SRDX 1979
- Country
- TNGX United States
- SRDX United States
- Employees
- TNGX N/A
- SRDX N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- SRDX Medical/Dental Instruments
- Sector
- TNGX Health Care
- SRDX Health Care
- Exchange
- TNGX Nasdaq
- SRDX Nasdaq
- Market Cap
- TNGX 413.6M
- SRDX 562.6M
- IPO Year
- TNGX N/A
- SRDX 1998
- Fundamental
- Price
- TNGX $3.13
- SRDX $39.68
- Analyst Decision
- TNGX Strong Buy
- SRDX Hold
- Analyst Count
- TNGX 8
- SRDX 4
- Target Price
- TNGX $13.14
- SRDX $43.00
- AVG Volume (30 Days)
- TNGX 1.4M
- SRDX 162.6K
- Earning Date
- TNGX 11-06-2024
- SRDX 01-30-2025
- Dividend Yield
- TNGX N/A
- SRDX N/A
- EPS Growth
- TNGX N/A
- SRDX N/A
- EPS
- TNGX N/A
- SRDX N/A
- Revenue
- TNGX $43,383,000.00
- SRDX $126,078,000.00
- Revenue This Year
- TNGX $27.73
- SRDX $13.75
- Revenue Next Year
- TNGX N/A
- SRDX $13.67
- P/E Ratio
- TNGX N/A
- SRDX N/A
- Revenue Growth
- TNGX 15.67
- SRDX N/A
- 52 Week Low
- TNGX $2.70
- SRDX $25.17
- 52 Week High
- TNGX $13.01
- SRDX $42.44
- Technical
- Relative Strength Index (RSI)
- TNGX 42.05
- SRDX 53.22
- Support Level
- TNGX $2.95
- SRDX $39.25
- Resistance Level
- TNGX $3.20
- SRDX $40.00
- Average True Range (ATR)
- TNGX 0.27
- SRDX 0.40
- MACD
- TNGX 0.08
- SRDX -0.08
- Stochastic Oscillator
- TNGX 72.88
- SRDX 46.74
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
About SRDX Surmodics Inc.
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.